Merus N.V. (MRUS), which recently secured its first FDA approval, is continuing to progress its pipeline of innovative full-length human bispecific and trispecific antibody therapeutics, known as Multiclonics. The company is also set to share updates on its clinical programs throughout this year.
The company's lead asset, Bizengri, whose chemical name is Zenocutuzumab, was granted accelerated approval by the FDA on December 4, 2024, for the treatment of NRG1 fusion-positive non-small cell lung cancer (NSCLC) and NRG1 fusion-positive pancreatic adenocarcinoma in patients who have had disease progression during or after prior systemic therapy.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com